[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350985-105":59,"doc-detail-350985-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-serine-synthesis-pathway-to-reverse-paclitaxel-resistance-in-nsclc-with-combination-of-paclitaxel-and-anlotinib-research-open-access","Targeting serine synthesis pathway to reverse paclitaxel resistance in NSCLC with combination of paclitaxel and anlotinib - Research Open Access","","Background: Paclitaxel (PTX) is a first-line chemotherapy for advanced non-small cell lung cancer (NSCLC), yet emerging PTX resistance threatens survival. The serine synthesis pathway (SSP) is activated in NSCLC and has been linked to resistance, but its specific role in PTX resistance is unclear. Methods: Integrated transcriptomic and metabolomic analyses plus in vitro and in vivo experiments assessed how SSP activation regulates PTX resistance and whether PTX combined with anlotinib overcomes resistance through SSP modulation. Results: SSP activation promotes proliferation of PTX-resistant NSCLC cells, enhances P-glycoprotein expression/transport, drives EMT, and preserves redox balance, while anlotinib synergizes with PTX by suppressing SSP, disrupting AKT/ERK signaling and P-gp, reversing EMT, disturbing redox homeostasis, increasing ROS, and activating mitochondrial apoptosis to induce cell death. Conclusion: PTX plus anlotinib via SSP inhibition is a promising strategy to overcome PTX resistance in NSCLC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-serine-synthesis-pathway-to-reverse-paclitaxel-resistance-in-nsclc-with-combination-of-paclitaxel-and-anlotinib-research-open-access/350985/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-serine-synthesis-pathway-to-reverse-paclitaxel-resistance-in-nsclc-with-combination-of-paclitaxel-and-anlotinib-research-open-access/350985.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in NSCLC?","Question",{"text":112,"@type":113},"It addresses paclitaxel (PTX) resistance in advanced NSCLC, which undermines chemotherapy efficacy and patient outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is the serine synthesis pathway (SSP) linked to PTX resistance?",{"text":117,"@type":113},"The study reports that SSP activation increases PTX resistance by enhancing PTX-resistant cell proliferation, P-glycoprotein expression and transport, EMT, and redox homeostasis.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the proposed treatment strategy to reverse PTX resistance?",{"text":121,"@type":113},"Combining anlotinib with PTX to suppress SSP, leading to reduced glycolysis, interruption of AKT/ERK proliferative signaling, inhibition of P-gp, EMT reversal, redox imbalance, increased ROS, and activation of mitochondrial apoptosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350985,1790541914,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Yu etal. Journal of Experimental & Clinical Cancer Research (2026) 45:30 [https://doi.org/10.1186/s13046-025-03627-w](https://doi.org/10.1186/s13046-025-03627-w)  \nJournal of Experimental & Clinical Cancer Research  \nRESEARCH Open Access  \nTargeting serine synthesis pathway   \nto reverse paclitaxel resistance in NSCLC with combination of paclitaxel and anlotinib  \nMengting Yu1, Yanyun Hong1, Qingshan Pan1, Pengwu Zheng1, Yingxing He2, Wufu Zhu1*, Shan Xu1* and Qiaoli Lv2*  \nAbstract  \nBackground Paclitaxel (PTX) serves as a first-line chemotherapeutic agent for the treatment of advanced non-small cell lung cancer (NSCLC) . However, the emergence of drug resistance poses a significant threat to patient survival. Theserine synthetic pathway (SSP) has been implicated in drug resistance across various cancers and is notably activated in NSCLC. Nevertheless, its role in PTX resistance remains poorly understood.  \nMethods In this study, we investigated the influence ofthe SSP on PTX resistance in NSCLC and explored a novel combination therapeutic strategy involving PTX and anlotinib to reverse NSCLC drug resistance. Specifically, using integrated transcriptomic and metabolomic analyses along with in vitro and in vivo experimental approaches, we aimed to elucidate the regulatory role of activated SSP in PTX resistance and to determine whether the combination of anlotinib and PTX can overcome PTX resistance in NSCLC through modulation ofthe SSP.  \nResults We found that SSP activation drives PTX resistance by promoting the proliferation of PTX-resistant NSCLC cells, increasing the expression and transport function of P-glycoprotein (P-gp), inducing epithelial-to-mesenchymal transition (EMT), and maintaining redox homeostasis. Anlotinib synergizes with PTX by suppressing SSP. This leads to attenuated glycolysis, disruption of the AKT/ERK proliferative signaling pathway, inhibition of P-gp expression and function, reversal of EMT, and redox imbalance, which subsequently elevates reactive oxygen species (ROS) levels and activates the mitochondrial apoptosis pathway, ultimately inducing apoptosis.  \nConclusion Collectively, our study demonstrates that anlotinib combined with PTX, via SSP inhibition, is a promising strategy for overcoming PTX resistance in NSCLC.  \nKeywords Non-small cell lung cancer, Serine synthesis pathway, Paclitaxel resistance, Anlotinib  \n*Correspondence: Wufu Zhu  \nzhuwufu-1 [122@163.com](122@163.com)  \nShan Xu [shanxu9891@126.com](shanxu9891@126.com)[ ](shanxu9891@126.com)Qiaoli Lv [lvqiaoli2008@126.com](lvqiaoli2008@126.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The)[. The](http://creativecommons.org/licenses/by/4.0/. The)[ ](http://creativecommons.org/licenses/by/4.0/. The)Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nYu et al. Journal of Experimental & Clinical Ca","cbCaimWfAyAV287I","https://ap.wps.com/l/cbCaimWfAyAV287I","pdf",27828706,21,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Current treatment and PTX resistance in NSCLC\n## Serine metabolism and SSP rationale","[{\"question\":\"What problem does the study address in NSCLC?\",\"answer\":\"It addresses paclitaxel (PTX) resistance in advanced NSCLC, which undermines chemotherapy efficacy and patient outcomes.\"},{\"question\":\"How is the serine synthesis pathway (SSP) linked to PTX resistance?\",\"answer\":\"The study reports that SSP activation increases PTX resistance by enhancing PTX-resistant cell proliferation, P-glycoprotein expression and transport, EMT, and redox homeostasis.\"},{\"question\":\"What is the proposed treatment strategy to reverse PTX resistance?\",\"answer\":\"Combining anlotinib with PTX to suppress SSP, leading to reduced glycolysis, interruption of AKT/ERK proliferative signaling, inhibition of P-gp, EMT reversal, redox imbalance, increased ROS, and activation of mitochondrial apoptosis.\"}]","Targeting serine synthesis pathway to reverse paclitaxel resistance in NSCLC with combination of paclitaxel and anlotinib - Research Open Access | PDF",1790092201,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0557d86bf8b3aa3301cba4f6c438d9c7.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a72bf9574dbad2d1949f8fdc33522d8.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2228dc1e0b28da9c87e40b8b4111d105.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a594bc98189e4519c77745c427bd44e.webp",980,1306]